<DOC>
	<DOC>NCT00700271</DOC>
	<brief_summary>This study was a multicenter, randomized, PROBE-type (prospective, randomized, open label, blinded end-point) study of 12 weeks duration comprising four visits, carried out in patients with essential arterial hypertension not controlled on four weeks treatment with amlodipine 5 mg alone.</brief_summary>
	<brief_title>Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age &gt;= 18 years Essential uncontrolled or naive hypertensive patients (SBP â‰¥= 140 mmHG, DBP &gt;/=90 mm Hg, or SBP &gt;= 130 mmHg, DBP &gt;= 80 mmHg if diabetes or renal impairment) except patients treated with amlodipine, or intolerant of ARBs and/or calcium channel blockers. Severe hypertension : SBP &gt;= 180 mmHg, DBP &gt;= 110mmHg Pregnancy Allergia to ARBs and/or to calcium channel blockers Antihypertensive tritherapy at V1 History of heart failure, pectoris angina, stroke, myocardial infarction Diabetes type I Renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>ambulatory blood pressure monitoring</keyword>
</DOC>